• Lundbeck’s earnings per share rose 30% year over year to DKK 4.11 in the first nine months of 2026.
• Revenue increased 9% to DKK 20.19 billion, supported by strong Vyepti growth and solid Rexulti contributions.
• Vyepti revenue jumped 39% to DKK 4.53 billion.
• Japan granted marketing authorization for eptinezumab to prevent migraine attacks in adults, expanding the treatment’s global reach.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. H. Lundbeck A/S published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.